Background-Several biomarkers have been individually associated with vascular brain injury, but no prior study has explored the simultaneous association of a biologically plausible panel of biomarkers with the incidence of stroke/transient ischemic attack and the prevalence of subclinical brain injury. Methods and Results-In 3127 stroke-free Framingham offspring (age, 59Ϯ10 years; 54% female), we related a panel of 8 biomarkers assessing inflammation (C-reactive protein), hemostasis (D-dimer and plasminogen activator inhibitor-1), neurohormonal activity (aldosterone-to-renin ratio, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptides), and endothelial function (homocysteine and urinary albumin/creatinine ratio) measured at the sixth examination (1995)(1996)(1997)(1998) 
S
troke is the fourth leading cause of death and is a major cause of long-term disability in America. Despite progress in acute treatment protocols, prevention remains the most effective approach to reduce the personal and public health impact of stroke. 1 The advent of sensitive brain imaging techniques has established that the burden of cerebrovascular disease is far greater than that of overt clinical disease. 2 In large population-based studies, the magnetic resonance imaging (MRI) findings of subclinical brain injury-presence of covert brain infarcts (CBIs), large white-matter hyperintensity volumes (LWMHVs), and smaller total cerebral brain volumes (TCBVs)-are common, with CBI prevalence rang-ing from 11% in younger subjects (Ͻ65 years of age) to 28% in older subjects. 3, 4 Although these subclinical findings do not cause abrupt clinical symptoms, they are often associated with subtle consequences such as cognitive decline 5 and motor function impairment 6 and have been associated with an increased risk of subsequent stroke. 7 
Clinical Perspective on p 2107
Vascular risk factors have also been implicated in subclinical brain injury, 3, 8 but the underlying pathophysiological pathways remain poorly understood. Several individual circulating and urinary biomarkers 9 -23 have been identified that lie along biologically plausible pathways that could lead to vascular brain injury. However, to the best of our knowledge, the relative contribution of these biomarkers from distinct biological pathways to an increased risk of both covert and overt vascular brain disease has not been explored. We hypothesized that select biomarkers will be associated with the presence of covert and/or the incidence of overt vascular brain disease in a large community-based, middle-aged cohort. We tested this hypothesis by relating a panel of 8 biomarkers-inflammation (C-reactive protein [CRP] ), hemostasis (D-dimer and plasminogen activator inhibitor-1), neurohormonal activity (aldosterone-to-renin ratio, B-type brain natriuretic peptide [BNP] , and N-terminal proatrial natriuretic peptide), and endothelial function (total homocysteine [tHcy] and urinary albumin/creatinine ratio [UACR])-to incident stroke/transient ischemic attack (TIA) prospectively and to prevalent subclinical brain disease in a large middle-aged community-based sample using a conservative statistical approach that minimized multiple testing.
Methods

Study Sample
In 1971, the Framingham Offspring Study was initiated with the enrollment of 5124 individuals who were either offspring of the original cohort participants or spouses of the offspring. 24 These participants have been assessed every 4 years, are currently undergoing their ninth examination, and remain under surveillance for incident stroke and TIA. Of 3532 participants who attended the sixth examination cycle (1995) (1996) (1997) (1998) at which biomarkers were measured, 3209 had biomarker information available; the remainder either did not undergo phlebotomy or had inadequate sample volume. Compared with those without biomarker data (nϭ323), the participants with available biomarker measures were younger and less likely to have diabetes mellitus or prevalent cardiovascular disease (Table I in the online-only Data Supplement).
We considered 2 study samples for the present investigation ( Figure I in the online-only Data Supplement). Among the 3209 participants with biomarker information, after exclusion of those with prevalent stroke (nϭ72) and those without subsequent stroke/ TIA follow-up information (nϭ10), 3127 participants (age, 59Ϯ10 years; 54% female) were eligible for investigation of the association between the panel of biomarkers and incident stroke/TIA (study sample 1). All participants who attended the seventh examination cycle were invited to undergo brain MRI (1999 -2005) . Of the 3209 who had biomarker information from the sixth offspring examination, 33 died before the start of the MRI study, 63 were excluded for prevalent dementia, and 10 were excluded for prevalent stroke at the time of MRI; 1173 persons either declined MRI or had a contraindication. After the additional exclusion of persons with another neurological illness (such as multiple sclerosis or brain tumor) that could affect MRI measurements, persons with a serum creatinine Ͼ2.0 mg/dL, and those with missing covariate data (nϭ29), 1901 participants (age, 58Ϯ10 years; 54% female) with both biomarkers and brain MRI measures available were eligible for investigation of the association between the panel of biomarkers and subclinical brain disease (study sample 2). Baseline characteristics comparing persons who were in our MRI study sample with those who had biomarker data but were not in our brain MRI analysis sample are shown in Table II in the online-only Data Supplement.
Biomarkers Measurements
We assessed 8 independent biomarkers from biologically plausible pathways implicated in the pathogenesis of overt and covert vascular brain injury. Plasma concentrations of each biomarker were routinely measured on previously frozen (stored) blood samples drawn in the fasting state from persons who attended the sixth examination cycle, and UACR was assessed in stored urine samples. All measurements were performed using previously reported methods specific for each biomarker 25 : High-sensitivity CRP levels were determined by Dade Behring BN100 nephelometer; plasma BNP and N-terminal proatrial natriuretic peptides were measured by high-sensitivity immunoradiometric assays; D-dimer and plasma plasminogen activator inhibitor-1 antigen were determined with a commercially available ELISA; serum aldosterone was measured from extracted and fractionated serum with radioimmunoassay; direct plasma renin was measured by immunochemiluminometric assay; and tHcy was measured with high-performance liquid chromatography with fluorometric detection. 23 The average interassay coefficients of variation for each biomarker were as follows: CRP, 2.2%; D-dimer, 11.7%; plasminogen activator inhibitor-1, 7.7%; aldosterone, 4.0% for high concentrations and 9.8% for low concentrations; renin, 2.0% for high concentrations and 10.0% for low concentrations; BNP, 12.2%; N-terminal proatrial natriuretic peptides, 12.7%; and tHcy, 9%. UACR (in milligrams per gram) was assessed on a morning urine specimen as the ratio between urinary albumin measured with immunoturbidimetry and urinary creatinine measured with a modified Jaffe method. The average interassay coefficients of variation for these 2 UACR assays were 7.2% and 2.3%, respectively.
Although the biomarkers were not measured at the same time as the initial brain MRI, we chose the sixth examination cycle as our baseline because (1) the entire panel of biomarkers was available at that examination, (2) this design increases the follow-up period available to study the risk of incident stroke/TIA, and (3) MRI changes accumulate over time, so previous rather than concurrent levels of biomarkers are more likely to be related to MRI markers of subclinical disease. 23 
Outcomes
Stroke and TIA (as a Composite Clinical Outcome)
Our stroke surveillance and protocol for determining the diagnosis and type of stroke have previously been published. All clinical events were ascertained by Ն2 neurologists at a consensus review. 26 Stroke was defined as an acute-onset focal neurological deficit of presumed or definite vascular origin that persisted for Ͼ24 hours. A TIA was defined clinically as a focal neurological deficit lasting Յ24 hours. We also used data on clinical features, imaging studies, and other laboratory criteria; data from noninvasive vascular studies; cardiac evaluations for a source of embolus; and, when available, information from autopsy studies.
Brain Imaging Measures (as a Subclinical Outcome)
MRI acquisition, measurement techniques, and interrater reliability have been described previously. 27 Briefly, the images were analyzed by operators blinded to the participant's demographics, exposure to stroke risk factors, and plasma biomarker levels. Brain volume was determined by manual delineation of the intracranial vault to determine the total cranial volume followed by subsequent mathematical modeling to determine total brain parenchymal volume (TCB). TCBV was then computed as a ratio of TCB to total cranial volume, representing a measure of brain parenchymal volume corrected for differences in head size. The volume of abnormal white-matter hyperintensity was determined according to previously published methods. 27 The participants were categorized as having LWMHVs if the log of the ratio of WMHV to total cranial volume was Ͼ1 SD above the age-adjusted mean in this cohort. The presence or absence of CBIs was determined manually by the operator on the basis of the size (Ͼ3 mm), location, and imaging characteristics of the lesion.
Definition of Covariates
Previously described and validated components of the Framingham Stroke Risk Profile were used as baseline covariates. 26 These include age, sex, systolic blood pressure, antihypertensive therapy, diabetes mellitus, smoking status, history of cardiovascular disease, and the presence of atrial fibrillation.
Statistical Analysis
All biomarkers that displayed skewed distribution were logtransformed to normalize their distributions. An age-adjusted Spearman correlation coefficient was calculated for each pair of biomarkers. The biomarker panel was related to the risk of incident stroke/TIA with Cox proportional hazards techniques and to subclinical MRI measures with linear (for continuous measures) or logistic (for binary measures) regression analyses. We used a 2-step analytic approach to minimize false positives resulting from multiple statistical testing. First, for each outcome, we used multivariable regression analysis to perform a global test of significance to examine whether the entire set of biomarkers was related to a given outcome.
In this step, we tested whether the set of 8 biomarkers (m1-m8) was associated with stroke/TIA risk using an 8-df likelihood ratio test of the null hypothesis H0: ␤ m1 ϭ␤ m2 …ϭ␤ m8 ϭ0. The likelihood ratio test 2 statistic was obtained by comparing likelihoods from 2 models: with the covariates only and with the covariates plus the 8 biomarkers. Subsequent analyses were performed only if the global P value was Ͻ0.05. If the biomarker panel was associated with the outcome of interest, then as a second step, we performed a stepwise multivariable regression with backward elimination to select a final parsimonious set of informative biomarkers associated with the outcome of interest using PϽ0.05 for retention in the final model. For clinical stroke/TIA, we also assessed the incremental utility of the identified individual biomarkers in predicting stroke/TIA risk by calculating net reclassification improvement using a more conventional logistic approach and a novel approach that allows for differences in survival times. 28, 29 We used clinically meaningful risk categories of Ͻ5%, 5% to 15%, and Ͼ15% 10-year stroke risks, 26, 28 defined a priori as risks experienced by the average person, at the baseline age of the current sample, in the presence of 0 (low risk), 1 or 2 (intermediate risk), or Ͼ2 (high risk) stroke risk factors included in the Framingham Stroke Risk Profile. 26 All analyses were adjusted for age and sex, baseline cardiovascular covariates, and serum creatinine. For the MRI analyses, we additionally adjusted for the time interval between baseline examination and time of MRI acquisition. Finally, we compared the magnitude of the association of specific biomarkers with TCBV with the impact of chronological age by dividing the regression coefficient for the biomarker by the regression coefficient for age, estimated with linear regression models.
Results
Study Samples
The baseline clinical characteristics and biomarkers levels are provided in Table 1 for the 2 study samples. The median follow-up period for stroke/TIA was 9.2 years (range, 0.5-11.9 years), and the median time interval between biomarker and subclinical brain MRI measurements was 3.5 years (range, 1.3-10.2 years). Pairwise age-adjusted Spearman correlations among selected biomarkers and of selected biomarkers with clinical covariates are given in Table 2 . The highest age-adjusted correlations were observed for BNP and N-terminal proatrial natriuretic peptides (rϭ0.60, PϽ0.001), CRP and D-dimer (rϭ0.33, PϽ0.001), and CRP and plasminogen activator inhibitor-1 (rϭ0. 29, PϽ0.001).
Association of Biomarker Panel and Stroke/TIA
We observed 130 incident stroke/TIA events in the 3127 participants; of these, 77 were strokes and 53 were TIAs. In multivariable analyses adjusted for traditional stroke risk factors (Table 3) , the biomarker panel was associated with an increased risk of stroke/TIA (global Pϭ0.001). On backward eliminations, only 2 biomarkers, BNP (Pϭ0.002) and UACR (Pϭ0.004), were retained in the final model. Higher BNP and UACR were each associated with an increased risk of stroke/TIA (hazard ratio, 1.39 per 1-SD increment in log-BNP; Pϭ0.002; and HR, 1.31 per 1-SD increment in log-UACR; Pϭ0.004). Adding these biomarker data to risk assessment models based on traditional stroke risk factors Tables III and IV in the onlineonly Data Supplement and in the Figure) . On secondary analyses, we found a similar association of higher BNP and UACR with an increased risk of stroke alone (HR, 1.28 per 1-SD increment in log-BNP; Pϭ0.04; and HR, 1.34 per 1-SD increment in log-UACR; Pϭ0.009).
Association of Biomarker Panel and Subclinical Brain MRI Measures
We further examined the association ( The impact of a single SD unit increase in plasma CRP or tHcy levels on TCBV was exactly equivalent to 1 year of brain aging, whereas 1-SD unit increases in D-dimer and log-UACR levels corresponded to 9 and 7 months, respectively, of brain aging.
Discussion
In our community-based, stroke-free middle-aged sample, we investigated a panel of 8 biologically plausible biomarkers for association with clinical and subclinical vascular brain injury.
In recent years, a large number of biomarkers have been individually associated with the risk of cerebrovascular disease. These biomarker levels are often correlated or interact with each other in complex ways, reflecting the actions of interrelated biological pathways. It is essential to identify a parsimonious set of maximally informative markers and to assess their relative contributions to risk prognostication if we are to improve on clinical risk prediction scores in a practical and cost-effective manner. We observed that the overall biomarker panel was associated with risk of stroke/TIA and with smaller brain volumes. We further identified that higher BNP levels and albuminuria were associated with the risk of initial incident stroke/TIA and that the addition of these biomarker data resulted in a modest improvement in categorizing stroke risk among participants. Albuminuria (but not BNP) was also associated with smaller total brain volume, as were higher CRP, D-dimer, and tHcy levels.
To the best of our knowledge, this is the first study to relate a large biomarker panel to both clinical and subclinical vascular brain injury. Our findings concur with prior observations that abnormalities in multiple biological pathways affect the risk of incident cardiovascular events (including stroke/TIA) and death. 25, 30 They confirm and extend to a middle-aged community sample prior reports describing the associations of several of these individual biomarkers with the risk of stroke/TIA or of subclinical brain disease, respectively.
Biological Pathways Underlying Stroke/TIA Risk
In previous reports, we had observed that elevated plasma CRP 9 and tHcy levels 23 were individually associated with an increased risk of stroke/TIA and that elevated UACR was associated with a higher risk of all cardiovascular disease events. 31 Using a multiple biomarker approach to evaluate the risk of all initial cardiovascular disease events (including stroke) in offspring, we had observed that BNP and UACR were associated with the risk of a major vascular event, but that study was underpowered to examine the outcome of stroke/TIA. 25 Our present data extend those observations by demonstrating associations of BNP and UACR with the risk of incident stroke/TIA using a longer follow-up period and including a larger number of incident stroke/TIA events. We did not confirm in the present investigation our previously reported observation of an association of CRP and tHcy with incident stroke/TIA, most likely because the present investigation evaluated a much younger sample that was associated with lower mean values of these particular biomarkers and hence was underpowered because of the smaller number of incident events. Interestingly, the effect size of the association between CRP and stroke/TIA in the present study was similar to what we had observed in the prior study, but it did not reach statistical significance. In addition, in prior reports, we have also observed that the mean tHcy levels were lower in the offspring at the sixth offspring examination (after dietary folate fortification was initiated) compared with the fifth offspring examination, which was before fortification. 32 Thus, lower levels of tHcy among participants included in the present study may have contributed to the lack of the association between tHcy levels and incident stroke/TIA.
BNP and Stroke/TIA
BNP is a natriuretic peptide with diuretic and vasodilatory activities released by cardiomyocytes during hemodynamic stress and cleared by the kidneys. 33 Elevated plasma levels of BNP have been observed in older patients, perhaps because of myocardial fibrosis and cardiac hypertrophy and/or secondary to renal dysfunction in otherwise healthy elderly persons, but also in persons with essential hypertension, left ventricular hypertrophy, diastolic dysfunction, atrial fibrillation, and renal failure. 33 As a biological marker, BNP is used for diagnostic and prognostic purposes in patients with chronic congestive heart failure and has been evaluated for the risk stratification of individuals with an acute coronary syndrome. 34 Most of the cardiac conditions mentioned above have been associated with the risk of stroke/TIA, 30 but an independent link between higher BNP levels and stroke/TIA risk observed in our middle-aged population after adjustment for blood pressure and cardiac and renal disease suggests there may be additional pathophysiological mechanisms. For example, an increased level of physical activity (which reduces stroke risk) may decrease BNP levels. 35 
Albuminuria and Stroke/TIA
Albuminuria has been associated with the risk of cardiovascular disease events and the presence of subclinical vascular disease in other organs, 25, 36 but its role in cerebrovascular disease is less clear, and only a few cohort studies have evaluated the association of albuminuria or microalbuminuria with stroke as a primary end point. 18 -20 Our findings concur with these prior reports. Although the underlying mechanism for this association is unclear, albuminuria is a known marker of glomerular endothelial dysfunction, has been associated with diffuse endothelial dysfunction in other vascular beds, 37, 38 and is a marker of cardiovascular target organ damage.
Biological Pathways Underlying Subclinical Vascular Brain Disease
In prior reports, we had demonstrated that the components of the Framingham Stroke Risk Profile and selected inflammatory markers are related to LWMH 8 and to brain atrophy, 11 respectively. We have also previously shown that elevated plasma tHcy levels are associated with an increased risk of CBI and smaller brain volumes. 23 Our present findings, however, identify additional biological pathways that may be involved in mediating brain atrophy.
Inflammation and Brain Volumes
Links between inflammation and brain atrophy and between lower TCBV and poorer cognitive performance have previously been reported. 11 However, the findings of an association between higher CRP levels and smaller brain volumes are novel. CRP is a marker of a chronic low-grade inflammation and a marker of endothelial dysfunction. As part of an innate immune system response, CRP deposits have been detected in brain microvessels. 39 Several cohort studies have observed increased CRP levels before the clinical onset of Alzheimer disease and/or vascular dementia, but brain MRI measurements were not described in these reports. 40, 41 Our failure to find an independent association between CRP and TCBV in an earlier report could reflect the smaller sample size in that investigation and the use of a later baseline examination cycle closer to the date of MRI in that study because inflammation likely affects brain volumes over months to years. Furthermore, it is possible that an association with CRP was obscured by a stronger association with a correlated inflammatory marker (interleukin-6), which was included in the previous report 11 but not in the present study (interleukin-6 levels were not available at the sixth examination, which served as the baseline). Because CRP is a commonly measured biomarker, we believe it could be a valuable contributor to a future multimarker panel for determining the risk of cerebrovascular injury.
Hemostasis and Brain Volumes
D-dimer as a marker of fibrinolytic turnover is present in very small amounts in a healthy population. Its role in the activation of coagulation in clinical and subclinical brain infarcts remains controversial. 13 Prior observations have suggested an association between hypercoagulability and brain atrophy in the elderly. 12 In the same report, increased levels of D-dimer have been associated with white-matter hyperintensities and Binswanger disease. 12 It is plausible that endothelial dysfunction and/or inflammation might trigger an alteration in the hemostatic pathways within the brain microvasculature/parenchyma and accelerate microvascular ischemia. However, further experimental and human studies are required to define these interactions.
Endothelial Function and Brain Volumes
Our previous observation that higher plasma tHcy levels predispose to smaller brain volumes 23 has been confirmed in this report. Homocysteine is an independent risk factor for atherosclerosis and cardiovascular disease. As an excitatory neurotransmitter, it binds to the NMDA receptors and leads to oxidative stress, endothelial dysfunction, and inflammation and neuronal injury. 42 Potential mechanisms through which tHcy could result in brain atrophy have been discussed briefly in a prior publication. 23 
Albuminuria and Brain Volumes
Albuminuria not only is an indicator of renal microvascular disease but also may reflect diffuse microvascular disease, endothelial dysfunction, and vascular damage (the Steno hypothesis). 37, 38 In a case-control study of patients with hypertension but no diabetes mellitus, microalbuminuria was independently associated with a higher prevalence of silent lacunar infarcts and greater carotid intima-media thickness. 43 As confirmed in our report, albuminuria has also been associated with stroke and brain atrophy. 18 -21 However, the mechanisms underlying this association remain unclear. It has been suggested that, with aging, endothelial dysfunction, intimal fibromuscular hyperplasia, and lipohyalinosis in cerebral microvas-culature might develop in parallel with vascular changes in the renal microvascular system. 21 The absence of an association between the biomarker panel and CBI and/or white-matter hyperintensity does not necessarily mean that such associations do not exist. It is plausible that, with the relatively younger age of our sample, we had limited statistical power to detect such associations.
Strengths and Limitations
The strengths of our study are the inclusion of a stroke-free, middle-aged study sample, their longitudinal follow-up with careful prospective surveillance of clinical events, the availability of a range of biomarkers measured by previously validated methods, the availability of baseline values for traditional stroke risk factors, and the availability of volumetric brain MRI measurements performed by radiologists blinded to clinical events and biomarker information. One limitation of our study is the predominantly white study sample, which limits the generalizability of our findings to other ethnicities/races. At present, we have only a single-occasion measurement for each biomarker and single brain MRI measurements. Furthermore, the subset of participants who underwent brain MRI and had biomarker data had a lower prevalence of vascular risk factors and was healthier than the rest of the Framingham offspring; this could potentially bias our results. Finally, we assessed the incremental prognostic value of BNP and UACR in predicting the risk of stroke/TIA using the net reclassification improvement and clinically reasonable cut points, but we recognize that changing the cut points used to define low-, intermediate-, and high-risk categories would vary the net reclassification improvement computed.
Conclusions
Alterations in several different biological pathways may underlie the pathophysiology of clinical and subclinical brain disease. Using a conservative multimarker approach, we identified 2 biomarkers associated with the risk of incident stroke and 4 biomarkers associated with a smaller brain volume in a middle-age, stroke-free sample. Urinary albuminuria, a comparatively less well-studied biomarker of cerebrovascular risk, was associated with both outcomes. However, both BNP and UACR increased the risk for stroke/TIA and offered modest improvements in the accuracy of risk classification. These findings should be taken into consideration when building risk stratification models and may point to novel, potentially synergistic preventive and therapeutic measures. Finally, the performance of such multimarker strategies in risk stratification for clinical and subclinical vascular disease requires further investigation, particularly in the current "omics" era, as the number of putative biomarkers expands at an exponential rate, providing both an opportunity and a challenge to develop improved, cost-effective risk prediction models.
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CLINICAL PERSPECTIVE
Numerous biomarkers representing various biological pathways have been independently implicated in cerebrovascular disease, but their relative contribution to the prediction of clinical cerebrovascular disease is uncertain. In a middle-aged community sample, we used a multimarker approach to identify plausible biomarkers associated with clinical and subclinical vascular brain injury. This approach also permitted us to assess the contribution of each biomarker to clinical risk reclassification after accounting for standard vascular risk factors that comprise the Framingham Stroke Risk Profile. In analyses adjusted for traditional risk factors, we observed an association between an aggregate panel of biomarkers, including markers of inflammation (C-reactive protein), hemostasis (D-dimer and plasminogen activator inhibitor-1), neurohormonal activity (aldosterone-to-renin ratio, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptides), and endothelial function (plasma homocysteine and urinary albumin/creatinine ratio), and the risk of stroke/transient ischemic attack and with magnetic resonance imaging brain volumes. In further analyses, we identified that higher B-type natriuretic peptide levels and albuminuria were associated with the risk of stroke/transient ischemic attack and that the addition of these biomarker data provided incremental information over clinical risk factors predicting stroke. We further indentified that albuminuria (but not B-type natriuretic peptide) was also associated with smaller brain volume, as were higher C-reactive protein, D-dimer, and plasma homocysteine levels. Our findings are consistent with prior observations that alterations in several different biological pathways may underlie the pathophysiology of clinical and subclinical brain disease. However, whether the knowledge of B-type natriuretic peptide and albuminuria may be used to target individuals at risk of stroke for more intense primary prevention or monitoring requires further investigation.
